MYX Stock Overview
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MYX from our risk checks.
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$6.72 |
| 52 Week High | AU$7.38 |
| 52 Week Low | AU$2.71 |
| Beta | 1.32 |
| 1 Month Change | -4.27% |
| 3 Month Change | 27.27% |
| 1 Year Change | 77.78% |
| 3 Year Change | -24.92% |
| 5 Year Change | -51.65% |
| Change since IPO | -59.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -5.5% | -5.0% | -3.1% |
| 1Y | 77.8% | 32.4% | 4.0% |
Return vs Industry: MYX exceeded the Australian Pharmaceuticals industry which returned 32.4% over the past year.
Return vs Market: MYX exceeded the Australian Market which returned 4% over the past year.
Price Volatility
| MYX volatility | |
|---|---|
| MYX Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: MYX has not had significant price volatility in the past 3 months.
Volatility Over Time: MYX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| MYX fundamental statistics | |
|---|---|
| Market cap | AU$547.75m |
| Earnings (TTM) | -AU$274.18m |
| Revenue (TTM) | AU$319.28m |
1.7x
P/S Ratio-2.0x
P/E RatioIs MYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYX income statement (TTM) | |
|---|---|
| Revenue | AU$319.28m |
| Cost of Revenue | AU$145.07m |
| Gross Profit | AU$174.21m |
| Other Expenses | AU$448.39m |
| Earnings | -AU$274.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -3.38 |
| Gross Margin | 54.56% |
| Net Profit Margin | -85.87% |
| Debt/Equity Ratio | 5.5% |
How did MYX perform over the long term?
See historical performance and comparison